If approved in the world's biggest pharmaceuticals market, GSK's vaccine, Arexvy, would be competing for a market share in ...

Moderna’s COVID-19 vaccine has received full approval from the US Food and Drug Administration (FDA) for use in children with medical conditions that put them at higher risk of severe illness.

GSK has applied to the US Food and Drug Administration (FDA) to extend use of its respiratory syncytial virus (RSV) vaccine Arexvy to adults under the age of 50 who are at increased risk of the ...

The company expects to make the updated Spikevax available to U.S. patients in time for the 2025-26 respiratory virus season.